Lantern Pharma Inc. (LTRN) is a publicly traded company in the Unknown sector. Across all available filings, 10 corporate insiders have executed 82 transactions totaling $6.5M, demonstrating a bearish sentiment with -$6.2M in net insider flow. The most recent transaction on Jul 24, 2024 involved a transaction of 3,832 shares valued at $12.0K.
No significant insider buying has been recorded for LTRN in the recent period.
No significant insider selling has been recorded for LTRN in the recent period.
Based on recent SEC filings, insider sentiment for LTRN is bearish with an Insider Alignment Score of 2/100 and a net flow of -$6.2M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Lantern Pharma Inc. (LTRN) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 10 insiders are actively trading LTRN stock, having executed 82 transactions in the past 90 days. The most active insider is Management, Lp Cavu (Executive), who has made 7 transactions totaling $2.0M.
Get notified when executives and directors at LTRN file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jul 24, 2024 | Jeffrey Keyser D. | Executive | Exercise | 3,832 | $3.13 | $12.0K | |
| May 24, 2024 | G.l. Fletcher Aaron | Executive | Sale | 1,859 | $6.33 | $11.8K | |
| May 24, 2024 | G.l. Fletcher Aaron | Executive | Sale | 13,888 | $6.33 | $87.9K | |
| May 24, 2024 | G.l. Fletcher Aaron | Executive | Sale | 4,253 | $6.33 | $26.9K | |
| May 24, 2024 | Llc Cavu Advisors, | Executive | Sale | 1,859 | $6.33 | $11.8K | |
| May 24, 2024 | Llc Cavu Advisors, | Executive | Sale | 13,888 | $6.33 | $87.9K | |
| May 24, 2024 | Llc Cavu Advisors, | Executive | Sale | 4,253 | $6.33 | $26.9K | |
| May 23, 2024 | G.l. Fletcher Aaron | Executive | Sale | 6,944 | $6.25 | $43.4K | |
| May 23, 2024 | G.l. Fletcher Aaron | Executive | Sale | 2,126 | $6.25 | $13.3K | |
| May 23, 2024 | G.l. Fletcher Aaron | Executive | Sale | 930 | $6.25 | $5.8K | |
| May 23, 2024 | Llc Cavu Advisors, | Executive | Sale | 930 | $6.25 | $5.8K | |
| May 23, 2024 | Llc Cavu Advisors, | Executive | Sale | 6,944 | $6.25 | $43.4K | |
| May 23, 2024 | Llc Cavu Advisors, | Executive | Sale | 2,126 | $6.25 | $13.3K | |
| Feb 29, 2024 | Lp Bp Directors, | Executive | Sale | 1,832 | $4.87 | $8.9K | |
| Feb 29, 2024 | Lp Bp Directors, | Executive | Sale | 4,185 | $4.87 | $20.4K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 54 | $6.4M | 89.8% |
Exercise (Options)(X) | 13 | $573.7K | 8.1% |
Purchase(P) | 1 | $150.0K | 2.1% |
Conversion(C) | 14 | $0 | 0.0% |
Insider selling pressure at Lantern Pharma Inc. has increased, with 10 insiders executing 82 transactions across all time. Total sales of $6.4M significantly outpace purchases of $150.0K, resulting in a net outflow of $6.2M. This selling activity appears largely discretionary, which may warrant closer attention from investors.